4/13
06:02 am
tvrd
Tvardi Therapeutics (TVRD) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Medium
Report
Tvardi Therapeutics (TVRD) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
4/3
07:22 am
tvrd
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium [Yahoo! Finance]
Low
Report
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium [Yahoo! Finance]
4/2
08:01 am
tvrd
Tvardi Therapeutics (TVRD) had its "buy" rating reaffirmed by BTIG Research. They now have a $15.00 price target on the stock.
Low
Report
Tvardi Therapeutics (TVRD) had its "buy" rating reaffirmed by BTIG Research. They now have a $15.00 price target on the stock.
4/2
08:00 am
tvrd
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Low
Report
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
4/1
03:15 pm
tvrd
Tvardi Therapeutics (TVRD) had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an "equal weight" rating on the stock.
Medium
Report
Tvardi Therapeutics (TVRD) had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an "equal weight" rating on the stock.
4/1
02:11 pm
tvrd
Tvardi Therapeutics (TVRD) had its price target lowered by Piper Sandler from $4.00 to $3.00. They now have a "neutral" rating on the stock.
Medium
Report
Tvardi Therapeutics (TVRD) had its price target lowered by Piper Sandler from $4.00 to $3.00. They now have a "neutral" rating on the stock.
3/31
04:34 pm
tvrd
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update [Yahoo! Finance]
Low
Report
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update [Yahoo! Finance]
3/31
04:01 pm
tvrd
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Medium
Report
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
3/8
01:31 am
tvrd
Low
Report
2/23
07:41 am
tvrd
Foghorn Therapeutics appoints Ryan Maynard as CFO [Seeking Alpha]
Medium
Report
Foghorn Therapeutics appoints Ryan Maynard as CFO [Seeking Alpha]
2/12
08:29 am
tvrd
Tvardi Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Tvardi Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/12
08:00 am
tvrd
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
2/5
06:10 am
tvrd
Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by analysts at Lucid Cap Mkts from a "hold" rating to a "strong-buy" rating.
Medium
Report
Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by analysts at Lucid Cap Mkts from a "hold" rating to a "strong-buy" rating.